| Name | Title | Contact Details |
|---|
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.
RxAlly was developed to provide a new solution to the critical issues of providing additional access to care and ensuring effective health care spending at a time when prescription medicine misuse is associated with $290 billion in annual costs. The RxAlly network of pharmacies aims to improve patient health through enhanced pharmacist care that combines clinical research, evidence-based clinical services and an interoperable technology platform.
Innov-X Systems Inc. is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fisher Clinical Services is a leader in providing clinical trial supply services. We are part of Thermo Fisher Scientific, the world leader in serving science. Thermo Fisher Scientific enables customers to make the world healthier, cleaner and safer by
Vantage BioTrials Inc. is a Dollard-Des-Ormeaux, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.